US stock movement: BillionToOne surged on September 24 due to liquid biopsy, performance growth, and prenatal screening

BillionToOne September 24th Surge Analysis

Keywords: liquid biopsy, performance growth, prenatal screening

1. On September 1st, the company launched the Northstar Origin liquid biopsy add-on project and expanded the Northstar Select testing panel from 84 genes to 102 genes, covering tissue origin prediction and cancer detection applications, further developing its molecular diagnostics product portfolio.

2. On August 5th, the company announced quarterly revenue of $109.4 million as of June 30th, a year-on-year increase of 64%; gross margin rose from 65% to 70%, net profit was $8.1 million, and the company maintained its 2026 revenue guidance at $450 million to $465 million.

3. On August 18th, the company released a prospective study covering 2,212 pregnant carriers, with a pregnancy outcome collection rate of 98.6%. The sensitivity of UNITY fetal risk screening was 94.4%, providing clinical data support for non-invasive prenatal testing products.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)